Answers are grounded in this paper and cite their sources.
allele burden was reduced and remained undetectable with response. Co-occurring mutations in NRAS and other MAPK pathway effectors were enriched in nonresponding patients, consistent with RAS signaling contributing to primary therapeutic resistance. Together, these data support differentiation as the main mechanism of enasidenib efficacy in relapsed/refractory AML patients and provide insight into resistance mechanisms to inform future mechanism-based combination treatment studies.
No takes yet. Share an insight, caveat, or question.
Amatangelo et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: